Disease Modifying Effect Of Bhallatakadi Churna In Amavata(Rheumatoid Arthritis)

A single armed clinical study to evaluate Disease Modifying Anti Rheumatic Drug (DMARD) effect of Bhallatakadi churna in Amavata w.s.r. to Rheumatoid Arthritis. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058251

Enrollment

Registered

2023-10-04

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects having classical signs and symptoms of Amavata and Rheumatoid arthritis(American College of Rheumatology). 3. On-going NSAID’s will be continued. 4. RA TITRE more than 20 IU/ml. 5. CRP more than 3mg/L. 6. Patients willing to give consent.

Exclusion criteria

Exclusion criteria: 1. Subject who are under Disease Modifying Anti Rheumatic Drug and Long actingSteroids. 2. Patients who underwent Panchakarma Line of treatment for 2weeks or more at the timeof interrogation. 3. Pregnant and Lactating women. 4. Patient with co-morbidity which is life threatening or interferes with the intervention

Design outcomes

Primary

Measure	Time frame
Validation of Bhallatakadi Churna as DMARD and its effect on symptoms of Amavata, RA Titre, CRP and ESR.Timepoint: 15Day,30day,45day	—

Secondary

Measure	Time frame
Safety of trial drug and Adverse drug reaction Aggravation of Symptoms of Amavata(RA)Timepoint: 15day, 30 day, 45 day	—

Countries

India

Contacts

Public ContactDr Amey Abhay Watwe

Sidramappa Danigond Memorial Trusts Ayurvedic Medical College Post Graduation Centre

drmsb123@rediffmail.com9036701207

Outcome results